We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Role of GIP in the Regulation of GLP-1 Satiety and Nausea.
- Authors
Hayes, Matthew R.; Borner, Tito; De Jonghe, Bart C.
- Abstract
Gastric inhibitory peptide (GIP) is best known for its role as an incretin hormone in control of blood glucose concentrations. As a classic satiation signal, however, the literature illustrates a mixed picture of GIP involvement with an at best weak anorectic response profile being reported for GIP receptor (GIPR) signaling. Not surprisingly, the pursuit of exploiting the GIP system as a therapeutic target for diabetes and obesity has fallen behind that of the other gastrointestinal-derived incretin, glucagon-like peptide 1 (GLP-1). However, recent discoveries highlighted here support potential therapeutic advantages of combinatorial therapies targeting GIP and GLP-1 systems together, with perhaps the most surprising finding that GIPR agonism may have antiemetic properties. As nausea and vomiting are the most common side effects of all existing GLP-1 pharmacotherapies, the ability for GIP agonism to reduce GLP-1-induced illness behaviors but retain (if not enhance) weight loss and glycemic control may offer a new era in the treatment of obesity and diabetes.
- Subjects
GLYCEMIC control; GLUCAGON-like peptide 1; PSYCHOLOGY of the sick; NAUSEA; WEIGHT loss; OBESITY; SATISFACTION; TYPE 2 diabetes; RESEARCH funding
- Publication
Diabetes, 2021, Vol 70, Issue 9, p1956
- ISSN
0012-1797
- Publication type
journal article
- DOI
10.2337/dbi21-0004